NCT06148935 - An Observational Study to Learn More About the Use of Vericiguat in Korean People With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF) in Real-world Setting | Biotech Hunter

Enrollment

3,000

Participants

Timeline

Start Date

November 30, 2023

Primary Completion Date

March 31, 2027

Study Completion Date

September 30, 2027

Conditions

Chronic Heart Failure With Reduced Ejection Fraction

Interventions

DRUG

Vericiguat (Verquvo, BAY1021189)

Following the manner of observational study, no intervention will be provided in the study. Participants follow locally approved label, without interference by the study initiator or study protocol

Trial Locations (1)

Unknown

RECRUITING

Many Locations, Multiple Locations